This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shuch, B. Articles by Osman, I. Search for Related Content PubMed PubMed Citation Articles by Shuch, B. Articles by Osman, I. Social Bookmarking                            What's this?

Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer

From the Departments of Urology, Pathology, and Medical Oncology, New York University Cancer Institute; and Departments of Biostatistics and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Iman Osman, MD, New York University School of Medicine, 550 First Avenue, H-100, New York, NY 10016; e-mail: Iman.Osman{at}med.nyu.edu

PURPOSE: The epidermal growth factor receptor (EGFR) plays a critical role in prostate cancer (PC) signal transduction and is the target of a novel class of anticancer agents. Despite recent reports of interethnic variation in response to EGFR inhibitors, limited information exists regarding differences in expression of EGFR in PC patients. This has therapeutic relevance because a better understanding of the molecular basis underlying the ethnic variability will help in the design of individualized treatment regimens using EGFR inhibitors.

PATIENTS AND METHODS: We investigated EGFR expression in a well-characterized cohort of PC patients to determine the association between EGFR expression and race. Tumor tissues from 202 radical prostatectomies performed between 1990 and 2000 at the Veterans Administration Medical Center (New York, NY) were studied (142 African Americans, 60 whites; median age, 67 years; stage T2, n = 130; stage T3, n = 72; Gleason score < 7, n = 110; Gleason score 7, n = 92). Membrane-specific EGFR expression was evaluated immunohistochemically.

RESULTS: EGFR overexpression, defined as complete membrane staining in more than 10% of tumor cells, was observed in 75 of 202 patients (37%). There was a significant association between EGFR overexpression and African American race (P = .0006), higher pretreatment prostate-specific antigen (PSA; P = .02), and stage (P = .02), but not Gleason score (P = .33). The association between African American race and EGFR overexpression remained significant in a multivariate model after controlling for grade, stage, and pretreatment PSA simultaneously (P = .003).

CONCLUSION: Our data demonstrate that race contributes significantly to variability of EGFR expression in prostate cancer. Racial background may have an impact on the design of clinical trials to test the efficacy of anti-EGFR agents.

Supported by National Institutes of Health/National Cancer Institute grants CA-01713 (I.O.). Supported in part also by the use of facilities at the Manhattan Veterans Administration Medical Center, New York, NY.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D.-S. Shin, H.-N. Kim, K. D. Shin, Y. J. Yoon, S.-J. Kim, D. C. Han, and B.-M. Kwon Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells Cancer Res., January 1, 2009; 69(1): 193 - 202. [Abstract] [Full Text] [PDF]

				T. Schlomm, P. Kirstein, L. Iwers, B. Daniel, T. Steuber, J. Walz, F. H.K. Chun, A. Haese, J. Kollermann, M. Graefen, et al. Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6579 - 6584. [Abstract] [Full Text] [PDF]

				B. A. Narayanan, B. S. Reddy, M. C. Bosland, D. Nargi, L. Horton, C. Randolph, and N. K. Narayanan Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence Clin. Cancer Res., October 1, 2007; 13(19): 5965 - 5973. [Abstract] [Full Text] [PDF]